Effect of High Levels of Oxygen and Smoking on the Lungs in Human Volunteers
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00001464|
Recruitment Status : Completed
First Posted : November 4, 1999
Last Update Posted : March 29, 2018
Patients with lung disease experiencing difficulty breathing can be treated with oxygen therapy. This involves the delivery of "extra" oxygen by a face-mask or through small tubes placed in the nose called nasal prongs. This extra oxygen can have concentrations as high as 100% pure oxygen. The concentration of oxygen in normal air is only 21%. The high concentration of oxygen can help to provide enough oxygen for all of the organs in the body. Unfortunately, breathing 100% oxygen for long periods of time can cause changes in the lungs, which are potentially harmful. Researchers believe that by lowering the concentration of oxygen therapy to 40% patients can receive it for longer periods of time without the risk of side effects.
This study is designed to evaluate the effects of oxygen therapy at 100% and 40% for 12 18 hours on the lungs of normal volunteers. Results of this study will help to determine if levels of oxygen therapy currently accepted as being "safe" may actually be damaging to the lungs.
|Condition or disease||Intervention/treatment||Phase|
|Healthy Hyperoxia||Procedure: Oxygen therapy||Phase 1|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||77 participants|
|Official Title:||Effect of Hypoxia and Smoking on Oxidation of Proteins and Nucleic Acids in Human Volunteers|
|Study Start Date :||August 1, 1995|
|Actual Primary Completion Date :||July 10, 2007|
|Actual Study Completion Date :||July 10, 2007|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00001464
|United States, Maryland|
|National Institutes of Health Clinical Center, 9000 Rockville Pike|
|Bethesda, Maryland, United States, 20892|
|Principal Investigator:||Joel Moss, M.D.||National Heart, Lung, and Blood Institute (NHLBI)|